Insmed provided new open-label extension data for treprostinil palmitil inhalation powder (TPIP) in pulmonary arterial hypertension. The company reported that patients in the treated arm maintained benefits over 24 months in a phase IIb extension, while placebo-assignment patients who switched to TPIP continued to show improvements after 12 months. The update reinforces the program’s central differentiator: once-daily dosing. Insmed noted that outcome measures were assessed 24 hours after the last TPIP administration, highlighting sustained exposure across the dosing interval. In the competitive PAH landscape where inhaled prostacyclin strategies vary by dosing frequency, the extension data add additional support for adherence and real-world manageability assumptions that companies often make when comparing inhaled regimens. For clinicians and product planners, the extension is a durability readout rather than a randomized endpoint, but it expands the evidence base for long-term tolerability and persistence of effect for a convenience-driven regimen.